In perspective, the novel functionalizedmutants, herein described, may pave the way for the development ofnew biologics to target the cancer cells overexpressing the PD-L1receptor, not only by inhibiting the PD-1/PD-L1 interaction but alsoby exerting a more direct cytotoxic and immunological activity. The gene discussed is PDCD1; the disease is cancer.